Already riding naloxone boom, Amphastar plots nasal spray to rival old formulas

A surge of opioid-related deaths in the U.S. has created an opportunity for pharma companies that make the overdose antidote naloxone. The drug's price has risen tenfold in recent years, Bloomberg reports, and state and local governments are shelling out to make it more widely available. One beneficiary? Amphastar Pharmaceuticals ($AMPH), which saw a 41% Q2 boost in revenue from its fully manufactured drugs. And the company is developing a ready-made naloxone nasal spray it hopes will pad its top line further. More

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.